Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
A ALIMENTARY TRACT AND METABOLISM
A10 DRUGS USED IN DIABETES
A10B BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
A10BJ Glucagon-like peptide-1 (GLP-1) analogues
A10BJ06 Semaglutide
D10025 Semaglutide (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Anti-Obesity Agents
Semaglutide
D10025 Semaglutide (USAN/INN)
Blood Glucose Regulators
Antidiabetic Agents
GLP-1 Receptor Agonist
Semaglutide
D10025 Semaglutide (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
2 Agents affecting individual organs
24 Hormones
249 Miscellaneous
2499 Others
D10025 Semaglutide (USAN/INN); Semaglutide (genetical recombination) (JAN)
Drug groups [BR:br08330]
Antidiabetic agent
DG02044 Hypoglycemic agent
DG01493 GLP-1 receptor agonist
D10025 Semaglutide
Drug classes [BR:br08332]
Antidiabetic agent
DG01493 GLP-1 receptor agonist
D10025 Semaglutide
DG02044 Hypoglycemic agent
D10025 Semaglutide
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Secretin receptor family
Glucagon
GLP1R
D10025 Semaglutide (USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D10025
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D10025
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D10025
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D10025
